18. Spinocerebellar degeneration Clinical trials / Disease details

Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05579691 (ClinicalTrials.gov)	September 21, 2022	5/10/2022	A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia	Friedreich Ataxia	Biological: CTI-1601;Other: Placebo	Larimar Therapeutics, Inc.	NULL	Recruiting	18 Years	N/A	All	15	Phase 2	United States
2	NCT04519567 (ClinicalTrials.gov)	July 31, 2020	17/8/2020	Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia	A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia	Friedreich Ataxia	Biological: CTI-1601;Biological: Placebo	Larimar Therapeutics, Inc.	Veristat, Inc.;Metrum Research Group, LLC	Completed	18 Years	N/A	All	27	Phase 1	United States
3	NCT04176991 (ClinicalTrials.gov)	December 11, 2019	14/11/2019	Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia	A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia	Friedreich Ataxia	Biological: CTI-1601;Biological: Placebo	Larimar Therapeutics, Inc.	Veristat, Inc.;Metrum Research Group, LLC	Completed	18 Years	N/A	All	28	Phase 1	United States